CNTN Tharimmune, Inc. Insider Trading

Gravitas Capital LP (Executive Chairman) bought 337,838 shares of THAR at $1.48 ($500.0K); stock down 69.0% from 52-week high, company unprofitable; 2 other insiders also bought in past 14 days.

Gravitas Capital LP purchased 337,838 shares for $500,000.24 at $1.48, increasing holdings by 85.6% to 732,424 shares total. The transaction occurs while THAR trades at $1.31, down 69.0% from its $4.22 52-week high and 10.3% lower over the past 90 days. The company reported a net income of $-2,541,704.00 for its most recent full fiscal year with a market capitalization of only $3,485,552.37. A cluster buy pattern is present, with 2 other insiders also purchasing shares within the 14 days prior to this transaction. This combination of sharply elevated executive ownership concentration amid depressed valuation and concurrent insider accumulation warrants scrutiny into whether this reflects conviction in a recovery thesis or other motivations.

CEO Appajosyula Sireesh bought 61,496 shares ($90,972.68) at $1.48 in 2 separate purchases; stock now trades at $1.31, down 69.0% from 52-week high of $4.22.

Appajosyula Sireesh, CEO of Tharimmune, Inc., executed two purchases totaling 61,496 shares for $90,972.68, increasing his holdings from 3.4K to 64.9K shares—a +1823.7% increase. The transaction occurs against a backdrop of significant deterioration in stock price: shares are currently $1.31, down 69.0% from the 52-week high of $4.22. His prior buy at THAR on 2024-11-13 resulted in a 90-day return of -5.4%, and the company reported a net income of -$2,541,704.00 over its most recent full fiscal year, indicating material unprofitability. A cluster pattern is present: 2 other insiders also bought within the past 14 days. The magnitude of the CEO's position accumulation combined with the concurrent insider buying activity and substantial stock price decline warrants examination of what fundamental or strategic information may underlie this concentrated buying at depressed valuations.

Director Parikh Sanam purchased 1,000 shares of THAR at $1.45; stock down 69.0% from 52-week high, company unprofitable ($-2.5M net income).

Parikh Sanam, a Director, purchased 1,000 shares at $1.45 on 2025-06-20, increasing his holdings by 129.9% to 1,770 shares. The stock is trading 69.0% below its 52-week high and down 10.3% over the past 90 days, creating a significantly depressed price environment. Tharimmune reported negative net income of $-2.5M on a $3.5M market cap, indicating the company is unprofitable. A cluster pattern is present, with 2 other insiders also buying within the past 14 days, suggesting potential coordinated confidence at these price levels. However, the insider's prior buy at THAR on 2025-05-15 showed a -0.8% 30-day return, and his broader track record across all tickers (1 prior buy) also averaged -0.8% 30-day returns, indicating that his recent purchase decisions have not yet translated into positive stock performance.

Director Sanam Parikh opens new position: 770 shares of THAR at $1.30 (now $1.33, -77.3% from 52-week high)

Director Sanam Parikh purchased 770 shares at $1.30 on 2025-05-15, establishing an initial position in Tharimmune, Inc. The company is unprofitable with net income of $-2,541,704.00 and a market cap of $3,538,766.91. At $1.33 current price, the stock trades -77.3% from its 52-week high of $5.86 but has recovered 20.9% over the past 30 days after a 90-day decline of -30.0%. This small open-market purchase by a director in a micro-cap biotech with ongoing losses occurs against a backdrop of severe valuation compression and volatile price action, warranting review of the underlying business trajectory.

CEO Randy Milby bought 4,600 shares at $2.12 on 2024-12-19; stock now -74.2% from 52-week high, company posted -$3.8M net income.

CEO Randy Milby purchased 4,600 shares (35.6% increase to holdings of 17,534 shares) at $2.12 on 2024-12-19, a deliberate accumulation in a deeply distressed position: the stock trades at $2.07, down 74.2% from its 52-week high of $8.02, and the company reported a net loss of $3,795,852.00 against a $3.1M market cap. His prior same-ticker buys at this company in late 2023 exhibited exceptional timing, with the 2023-12-15 purchase returning +1219.9% over 30 days and +1000.4% over 90 days, and the 2023-11-30 purchase returning +663.5% over 30 days and +507.5% over 90 days—both well-timed at the 90-day mark. However, his more recent October 2024 purchases at the same ticker have only posted modest 15–17% 30-day gains with no 90-day outcome yet measurable, suggesting the earlier outsized gains have not repeated. The purchase occurs in a sharply declining 30-day (-17.2%) and 90-day (-27.1%) window, and the company's negative profitability signals operational distress rather than a temporary valuation trough. While his cross-ticker track record shows 100% win rate over 90 days with +754.0% average return across 5 prior buys, that same-ticker pattern has compressed significantly in recent months, warranting scrutiny of whether current fundamentals justify further accumulation.

COO Sireesh bought 5,000 THAR shares at $2.02; holdings doubled to 10.8K. Stock down 97.2% from $78.75 high; co. posted -$3.8M net income.

Appajosyula Sireesh, Chief Operating Officer, purchased 5,000 shares at $2.02 on 2024-11-13, doubling his open-market position from 5,758 to 10,758 shares. The purchase follows a prior buy at the same ticker on 2024-10-08 (which showed a +25.9% 30-day return). The company is trading at $2.18, down 97.2% from its 52-week high of $78.75, reflecting a dramatic valuation collapse. Concurrent with this severe price decline, Tharimmune reported a full fiscal year net loss of -$3,795,852 ($-3.8M) on a market cap of only $3,239,560.66 ($3.2M), indicating the company is deeply unprofitable relative to its market value. The timing of this insider accumulation during an extreme drawdown warrants monitoring of both company fundamentals and market conditions to determine whether the execution reflects informed judgment or exposure to deteriorating operations.

COO Sireesh buys 5,000 THAR shares at $1.93 as stock plunges 97.9% from $97.50 high

Appajosyula Sireesh, Chief Operating Officer of Tharimmune, purchased 5,000 shares at $1.93, increasing his holdings by 44.0% to 16,364 shares. The purchase occurs against a backdrop of severe stock deterioration: the current price of $2.03 sits 97.9% below the 52-week high of $97.50, with the stock down 32.3% over 30 days and 44.5% over 90 days. The company remains unprofitable with a full-year net income of -$2,325,057.00 and a market cap of only $2,331,982.80. An insider acquisition at depressed valuations from a company's leadership warrants scrutiny given the company's negative earnings trajectory and the magnitude of the stock's prior collapse.